PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

The literature review of a surgery-urology
Article published in Urologia Polska 2001/54/2.

authors

Andrzej Borkowski, Tomasz Borkowski

references

  1. [1] Altaian AX., Haas Ch., Dutchman K.I I. i vvsp.: Selective nono-perative management ofblunt grade 5 renal injury. J.Urol .2000;
  2. 164:27-31.
  3. [2] Vieweg J.: The evolving role of dendritic cell therapy in urologie oncology. Current Opinions in Urology 2000; 10: 307-312.
  4. [3] Querschi K.N.. Nagubib R.N.G.. Hamdy C. i wsp.: Neural network of clinicopathological and molecular markers in bladder cancer. J. Urol. 2000: 163: 630-633.
  5. [4] I .ancelin F.. Anidjar M.. Villette J.M. i wsp.: Telomerase activity as a potential murker in preneoplastic bladder lesions. BJU In-lemailional 2000; 85: 526-531.
  6. [5] l-lerr I I.W.: Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-years outcome. J. Urol. 2000; 163: 60-62.
  7. [6] Lebrei Th., Bohin D.. Kassardijan Z. i wsp.: Recurrence, pirtgressio-nand.suceess in stage Ta grade 3 bladder tumors Heated with low dose Bacillus Calmette-Guerin instillations. J. Urol. 2000; 163: 63-67.
  8. [7] Kondylis F.I., Demirci S., Ladaga L. i wsp.: Outcomes after intravesical Bacillus Calmette-Guerin are not affected by sub-staging of high grade Tl transitional cell carcinoma. J. Urol. 2000; 163: 1120-1 123.
  9. [8] Lamm D.L.: Preventing progression and improving survival with BCG maintenance. Rur. Urol. 2000: 37(suppl 1): 9-15.
  10. [9] Lamm D.L., Blumenslein D.A.. Crissman J.D. i wsp.: Maintenence Bacillus Calmette-Guerin immunotherapy for recurrent Ta, Tl and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J. Urol. 2000; 163, 1124-1129.
  11. [10] Zlotta A. R., Van Vooren J.P., Huygen K.: What is the optimal regimen for BCG intravesical therapy. EurUrol 2000; 37, 470-477.
  12. [11] Pavlovich Ch.R, Kraling B.M., Stewart R.J. i wsp.: BCG-I ndu-ced urinary cytokines inhibit microvascular endothelial cell proliferation. J. Uro.l 2000; 163: 2014-2021.
  13. [12] Durek C, Rusch-Oerdes S., Jocham D. i wsp.: Sensivity of BCG to modem antibiotics. Eur. Urol. 2000; 37(suppl I): 21-25.
  14. [13] Steinberg G., Bahnson R., Brosman S. i wsp.: Efficacy and safety of Valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J. Urol. 2000; 163,47-52.
  15. [14] Kaasinen E.. Rintala E.. Pere A-K.: Weekly Mitomycin C followed by monthly Bacillus Calmette-Guerin or alternating monthly Interferon-alfalB and Bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. J. Urol. 2000; 164: 47-52.
  16. [15] Ghoneim M.A., El-Mekresh M.M., Mokhtar A.A. i wsp.: A predictive model of survival after cystectomy for carcinoma of the bladder. BJU International 2000: 85: 811-816.
  17. [16] Ennis R.D.. Petrylak D.P.. Singh P. i wsp.: The effect of cystectomy, and perioperative methotrexate. Vinblastine. Doxorubicin and Cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer. J. Urol. 2000: 163. 1413-1418.
  18. [17] Cheng L., Weaver A.L.. Bostwick D.: Predicting extravesical extension of bladder carcinoma: a novel method based on micrometer measurement of the depth of invasion in transurethral resection specimens . Urology 2000; 55, 668-672.
  19. [18] Baltaci S., Orhan D., Soyupek S. i wsp.: Influence of tumor stage, size, grade vascular involvement, histological cell type and histological pattern on multifocality of renal cell carcinoma. J. Urol. 2000: 164,36-39.
  20. [19] Fergany A.F.. Hafez K.S.. Novick Ac.: Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-yearsfollowup.S. Uro.l 2000: 163,442-445.
  21. [20] Black P.. Filipas D., Fichtner J. i wsp: Nephron sparing singery for central renal tumors: experience with 33 cases. J. Uro. 2000: 16:637-743.
  22. [21] Herr H.W.: Radiographic vs surgical size of renal tumours after partial nephrectomy. BJU Imemationalis 2000; 85, 19-21.
  23. [22] McClellan VI., Shawker T.H., Libutli S.K. i wsp.: A phase 2study of radio frequency interstitial tissue ablation of localized renal tumors. J. Urol. 2000, 163, 1424-1427.
  24. [23] Wolf J.S., Seifman B.D.. Vlontie J.E.: Nephron sparing surgery for suspected malignancy: open surgery compared to laparoscope\' with selective use of hand assistance. J. Urol. 2000: 163: 1659-1664.
  25. [24] Jabbbour M.E., Desgrandchamps F„ Cazin S.: Percutaneous management of grade II upper urinary tract transitional cell carcinoma: the long-term outcome. J. Urol. 2000; 163. 1105-1107.
  26. [25] Shalhav A.L., Dunn M.D.. Portis A.J. i wsp.: Laparoscopic ne-phroulerectomy for upper tract transitional cell cancer: the Washington university experirttce. J. Urol. 2000; 16.3: 1100-1104.
  27. [26] Jhavcri F.M., Klein R.A., Kupelian P.A. i wsp.: Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration J. Clin. Oncol. 1999; 17: 3167-3172.
  28. [27] Schroeder F.H.. van der Cruijsen-Koetcr I., de Koning H..I. i wsp.: Prostate cancer detection at low prostate specific antigen. .1. Urol. 2000; 163:806-812.
  29. [28] Horan A.H., McGehee M.: Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy. BJU International 2000: 85: 1063-1066.
  30. [29] Shaneyfelt T.. Huscin R, Bubley G I wsp. Hormonal predictors of prostate cancer: a meta-analysis. J. Clin. Oncol. 2000: 18, 847-853.
  31. [30] Sella A., Konichezky M., Flex D. i wsp.: Low PSA metastatic an-drogen-independentprostate cancer. Cur. Urol. 2000; 38.250-254.
  32. [31] Noguchi M., Stamey T.A.. McNcal J.E. i wsp..- An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J.Urol. 2000: 163: 1751-1755.
  33. [32] Haese A., Becker Ch., Noldus J. i wsp.: Human glandular kalli-krein 2: a potential serum marker for predicting the organ con-fied versus nonorgan conjied growth of prostate cancer. J. Urol. 2000; 163: 1491-1497.
  34. [33] Chang S.S., Gaudin P., ReuterV.E. i wsp.: Prostate-specific membrane antigen: present and future applications Urology 2000; 55. 622-629.
  35. [34] Klein A.E.. Zippe C.G.: Editorial: Transrectal ultrasound guided prostate biopsy-defining a new standard. J. Uro.l 2000: 163: 179-180.
  36. [35] Ravery V., Chastang C. Toublanc Mi wsp.: Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for TI-T2 prostate cancer. Eur.Urol. 2000: 37. 449-455.
  37. [36] Djavan B., Zlotla A., Remzi S. i wsp.: Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 men. J. Urol. 2000; 163. 1144-1149.
  38. [37] Agraval D.K., Coslello A.J., Peters J.: Differential response of prostate specific antigen to testosterone surge after luteinizing hormo-ne-ix\'leasing hormone analogue in prostate cancer and benign prostatic hyperplasia. BJU lnlemaiionalis 2000; 85: 690-695.
  39. [38] Lindert K.A.. Kabalin J.N., Terris M.K.: Bacteremia and bacte-riuria after transrectal itltrasoii guided prostate biopsy. .1. Urol. 2000: 164:76-80.
  40. [39] John H., Hauri D.: Seminal vesicle-sparing radical prostatectomy: a novel concept to restore early urinary continence. Urology 2000: 55, 820-824.
  41. [40] Walsh P.C.: Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. .I.Urol. 2000; 163, 1802-1807.
  42. [41] Flamffl Th.. Chauveinc L.. Servois V. i wsp.: La curietherapie dans le traitement curatifdu cancer de la prostate localize. Progres en Urologie 2000. 10, 3-13.
  43. [42] Critz F.A., Williams H.. Benlon J.B. i wsp.: Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J. Urol. 2000: 163: 1085-1089.
  44. [43] Amling Ch.L., Bltile M.L., Bergstrralh E.J. i wsp.: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5years. J.Urol. 2000: 164: 101-105.
  45. [44] Stamey T.A.. Yemolo Ch.M., McNcal J.E. i wsp.: Prostate cancer is highly predictable: a prognostic equitation based on all morphological variables in radical prostatectomy specimens. .1. Urol. 2000; 163: 1155-1160.
  46. [45] Leibovich B.C., Engen D.E.. Patterson D.E. i wsp.: Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J. Urol. 2000; 163: 1178-1182.
  47. [46] Cal C. Uslu R.. Gimaydin G. i wsp.: Doxazosin: a new cytotoxic agent for prostate cancer? BJU Intemationalis 2000; 85: 672-675.
  48. [47j Farrugia D.. Ansell W.. Singh M. i wsp.: Siilboestml plus adrenal suppression as a salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU lnlemaiionalis 2000: 85: 1069-1073.
  49. [48] Prostate cancer trialists\' collaborative group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000; 355. 1491-1498.
  50. [49] Pfcifcr B.L., Pirani J.E, Hainann S.R. i wsp.: PC-SPESa dietary supplement for the treatment of hormone-refractory prostate cancer. BJU lnlemaiionalis 2000; 85: 481-485.
  51. [50] Marek Lipiński, Marek Wrona. Leszek Jeromin Ocfclcin M.G.. Corntim R.: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J. Urol. 2000. 164, 726-729.